UroGen Pharma Ltd. (FRA:UR8)
Germany · Delayed Price · Currency is EUR 24.40
-0.60 (-2.40%)
Last updated: Dec 1, 2025, 8:10 AM CET
UroGen Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 90.04 | 171.99 | 95 | 55.41 | 44.36 | 52.86 | Upgrade |
Short-Term Investments | 36.99 | 64.7 | 41.97 | 44.56 | 44.78 | 49.15 | Upgrade |
Cash & Short-Term Investments | 127.03 | 236.69 | 136.97 | 99.96 | 89.14 | 102.02 | Upgrade |
Cash Growth | -49.10% | 72.80% | 37.02% | 12.14% | -12.62% | -30.64% | Upgrade |
Receivables | 19.7 | 20.3 | 15.44 | 12.7 | 11.72 | 7.05 | Upgrade |
Inventory | 8.34 | 9.23 | 5.67 | 4.33 | 4.83 | 1.96 | Upgrade |
Prepaid Expenses | 12.12 | 8.85 | 10.28 | 11.1 | 7.48 | 3.36 | Upgrade |
Restricted Cash | 1.35 | 1.08 | 0.82 | 0.81 | 1.23 | 1.23 | Upgrade |
Total Current Assets | 168.55 | 276.14 | 169.19 | 128.91 | 114.39 | 115.62 | Upgrade |
Property, Plant & Equipment | 9.18 | 3.79 | 2.36 | 3.75 | 3.15 | 4.2 | Upgrade |
Long-Term Investments | 0.38 | 5.02 | 4.5 | - | 0.68 | 1.89 | Upgrade |
Other Long-Term Assets | 6.94 | 0.77 | 2.26 | 2.96 | 1.53 | 0.29 | Upgrade |
Total Assets | 185.05 | 285.71 | 178.31 | 135.62 | 119.75 | 122.01 | Upgrade |
Accounts Payable | 10.28 | 10.93 | 6.51 | 5.53 | 5.79 | 3.27 | Upgrade |
Accrued Expenses | 27.01 | 27.07 | 20.84 | 15.11 | 13.26 | 16.31 | Upgrade |
Current Portion of Leases | 1.59 | 1.53 | 0.82 | 0.94 | 1.09 | 1.2 | Upgrade |
Other Current Liabilities | 3.37 | 6.42 | 3.04 | 2.34 | 2.24 | 0.66 | Upgrade |
Total Current Liabilities | 42.24 | 45.95 | 31.21 | 23.92 | 22.38 | 21.44 | Upgrade |
Long-Term Debt | 122.11 | 121.73 | 98.55 | 97.54 | - | - | Upgrade |
Long-Term Leases | 6.24 | 1.65 | 0.84 | 1.59 | 0.4 | 1.5 | Upgrade |
Other Long-Term Liabilities | 129.86 | 125.18 | 112.92 | 101.94 | 88.56 | 2.72 | Upgrade |
Total Liabilities | 300.45 | 294.51 | 243.52 | 224.98 | 111.33 | 25.65 | Upgrade |
Common Stock | 0.13 | 0.12 | 0.09 | 0.06 | 0.06 | 0.06 | Upgrade |
Additional Paid-In Capital | 817.79 | 797.25 | 614.04 | 487.79 | 475.7 | 452.53 | Upgrade |
Retained Earnings | -933.35 | -806.22 | -679.35 | -577.1 | -467.32 | -356.5 | Upgrade |
Comprehensive Income & Other | 0.02 | 0.06 | 0.01 | -0.11 | -0.03 | 0.27 | Upgrade |
Total Common Equity | -115.41 | -8.8 | -65.21 | -89.36 | 8.41 | 96.36 | Upgrade |
Shareholders' Equity | -115.41 | -8.8 | -65.21 | -89.36 | 8.41 | 96.36 | Upgrade |
Total Liabilities & Equity | 185.05 | 285.71 | 178.31 | 135.62 | 119.75 | 122.01 | Upgrade |
Total Debt | 129.94 | 124.92 | 100.21 | 100.06 | 1.49 | 2.7 | Upgrade |
Net Cash (Debt) | -2.53 | 116.79 | 41.26 | -0.1 | 88.33 | 101.21 | Upgrade |
Net Cash Growth | - | 183.09% | - | - | -12.73% | -47.13% | Upgrade |
Net Cash Per Share | -0.05 | 2.72 | 1.43 | -0.00 | 3.95 | 4.65 | Upgrade |
Filing Date Shares Outstanding | 46.81 | 46.09 | 34.12 | 23.44 | 22.67 | 22.27 | Upgrade |
Total Common Shares Outstanding | 46.78 | 42.23 | 32.49 | 23.13 | 22.46 | 22.17 | Upgrade |
Working Capital | 126.3 | 230.19 | 137.97 | 104.99 | 92.01 | 94.18 | Upgrade |
Book Value Per Share | -2.47 | -0.21 | -2.01 | -3.86 | 0.37 | 4.35 | Upgrade |
Tangible Book Value | -115.41 | -8.8 | -65.21 | -89.36 | 8.41 | 96.36 | Upgrade |
Tangible Book Value Per Share | -2.47 | -0.21 | -2.01 | -3.86 | 0.37 | 4.35 | Upgrade |
Machinery | 4.58 | 4.31 | 4.02 | 3.83 | 3.58 | 2.83 | Upgrade |
Leasehold Improvements | 0.63 | 0.63 | 0.62 | 0.62 | 0.62 | 0.61 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.